In last part, we found that JKAP expression in intestinal mucosa was negatively correlated with clinical activity in IBD patients and we then investigated whether IFX treatment could up-regulate JKAP expression in IBD patients. This evidence concerns the gene DUSP22 and inflammatory bowel disease.